Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients

Open access
Pietrobon, Anna Julia, Andrejew, Roberta, Custódio, Ricardo Wesley Alberca, Oliveira, Luana de Mendonça, Scholl, Juliete Nathali, Teixeira, Franciane Mouradian Emidio, de Brito, Cyro Alves, Glaser, Talita, Kazmierski, Julia, Goffinet, Christine, Turdo, Anna Claudia, Yendo, Tatiana, Aoki, Valeria, Figueiró, Fabricio, Battastini, Ana Maria, Ulrich, Henning, Benard, Gill, Duarte, Alberto Jose da Silva, Sato, Maria Notomi · 2022 · Frontiers in Immunology

Abstract

Ectonucleotidases modulate inflammatory responses by balancing extracellular ATP and adenosine (ADO) and might be involved in COVID-19 immunopathogenesis. Here, we explored the contribution of extracellular nucleotide metabolism to COVID-19 severity in mild and severe cases of the disease. We verified that the gene expression of ectonucleotidases is reduced in the whole blood of patients with COVID-19 and is negatively correlated to levels of CRP, an inflammatory marker of disease severity. In line with these findings, COVID-19 patients present higher ATP levels in plasma and reduced levels of ADO when compared to healthy controls. Cell type-specific analysis revealed higher frequencies of CD39+ T cells in severely ill patients, while CD4+ and CD8+ expressing CD73 are reduced in this same group. The frequency of B cells CD39+CD73+ is also decreased during acute COVID-19. Interestingly, B cells from COVID-19 patients showed a reduced capacity to hydrolyze ATP into ADP and ADO. Furthermore, impaired expression of ADO receptors and a compromised activation of its signaling pathway is observed in COVID-19 patients. The presence of ADO in vitro, however, suppressed inflammatory responses triggered in patients’ cells. In summary, our findings support the idea that alterations in the metabolism of extracellular purines contribute to immune dysregulation during COVID-19, possibly favoring disease severity, and suggest that ADO may be a therapeutic approach for the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.1012027

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Altered expression of nucleotidases and purinergic composition in the blood of COVID-19 patients. (A) Gene expression of nucleotidases ENPP1, ENPP2, ENPP3, ENTPD5, ENTPD1 (CD39) and NT5E (CD73) in whole blood of healthy donors (n=8) and COVID-19 patients (Mild hospitalized, n=10; Severe, n=10). (B) Negative correlation between the expression of nucleotidases and blood levels of C-reactive protein (CRP) in COVID-19 patients. (C) Plasma levels of ATP and ADO in healthy donors (n=14) and COVID-19 patients (Mild hospitalized, n=23; Severe, n=21). Data are shown as the median. One-way ANOVA test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Spearman’s correlation test was used to determine the correlation coefficient (r) and the significance (p<0.05). Blue dots indicate healthy donors (HD) whereas orange and red dots indicate hospitalized patients with mild and severe (Sev) COVID-19, respectively.
Figure 1 Altered expression of nucleotidases and purinergic composition in the blood of COVID-19 patients. (A) Gene expression of nucleotidases ENPP1, ENPP2, ENPP3, ENTPD5, ENTPD1 (CD39) and NT5E (CD73) in whole blood of healthy donors (n=8) and COVID-19 patients (Mild hospitalized, n=10; Severe, n=10). (B) Negative correlation between the expression of nucleotidases and blood levels of C-reactive protein (CRP) in COVID-19 patients. (C) Plasma levels of ATP and ADO in healthy donors (n=14) and COVID-19 patients (Mild hospitalized, n=23; Severe, n=21). Data are shown as the median. One-way ANOVA test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Spearman’s correlation test was used to determine the correlation coefficient (r) and the significance (p<0.05). Blue dots indicate healthy donors (HD) whereas orange and red dots indicate hospitalized patients with mild and severe (Sev) COVID-19, respectively.CC BY · PubMed Central
Figure 2 Altered frequency of CD39+ and CD73+ leucocytes in the blood of COVID-19 patients. Frequency and expression of CD39 and CD73 in (A) CD4+ T cells, (B) CD8+ T cells and (C) CD19+ cells from healthy donors (n=14) and COVID-19 patients (Mild hospitalized, n=14-21; Severe, n=12-24) based on the percentage of positive cells and the median of fluorescence (MFI) values. (D) Concentration of plasmatic CD73 from healthy donors (n=13) and COVID-19 patients (Mild hospitalized, n=25; Severe, n=24). (E) Heatmap of average gene expression values for ENPP1, ENPP2, ENPP3, ENTPD1, and NT5E in B cells, CD4+ T cells, and CD8+ T cells exposed or not to SARS-CoV-2. One-way ANOVA test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Blue dots indicate healthy donors (HD) whereas orange and red dots indicate hospitalized patients with mild and severe (Sev) COVID-19, respectively.
Figure 2 Altered frequency of CD39+ and CD73+ leucocytes in the blood of COVID-19 patients. Frequency and expression of CD39 and CD73 in (A) CD4+ T cells, (B) CD8+ T cells and (C) CD19+ cells from healthy donors (n=14) and COVID-19 patients (Mild hospitalized, n=14-21; Severe, n=12-24) based on the percentage of positive cells and the median of fluorescence (MFI) values. (D) Concentration of plasmatic CD73 from healthy donors (n=13) and COVID-19 patients (Mild hospitalized, n=25; Severe, n=24). (E) Heatmap of average gene expression values for ENPP1, ENPP2, ENPP3, ENTPD1, and NT5E in B cells, CD4+ T cells, and CD8+ T cells exposed or not to SARS-CoV-2. One-way ANOVA test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Blue dots indicate healthy donors (HD) whereas orange and red dots indicate hospitalized patients with mild and severe (Sev) COVID-19, respectively.CC BY · PubMed Central
Figure 3 Decreased hydrolysis of ATP by COVID-19 patients’ B cells. Isolated B cells from healthy donors (n=7) and COVID-19 patients (Severe, n=6) were incubated with 500 μM of ATP for 15, 30, and 60 minutes. Consumption of ATP (A) and production of ADP (B), AMP (C), and ADO (D) was accessed. Data shown as mean with SD. Two-way ANOVA with Bonferroni’s post-test for multiple comparisons: *p<0.05, **p<0.01, ***p<0.001. Blue lines indicate healthy donors (HD) whereas red lines indicate patients with severe (Sev) COVID-19.
Figure 3 Decreased hydrolysis of ATP by COVID-19 patients’ B cells. Isolated B cells from healthy donors (n=7) and COVID-19 patients (Severe, n=6) were incubated with 500 μM of ATP for 15, 30, and 60 minutes. Consumption of ATP (A) and production of ADP (B), AMP (C), and ADO (D) was accessed. Data shown as mean with SD. Two-way ANOVA with Bonferroni’s post-test for multiple comparisons: *p<0.05, **p<0.01, ***p<0.001. Blue lines indicate healthy donors (HD) whereas red lines indicate patients with severe (Sev) COVID-19.CC BY · PubMed Central
Figure 4 Impaired ADO signaling in COVID-19 patients. (A) Gene expression of ADORA1, ADORA2A, ADORA2B, and ADORA3 in whole blood of healthy donors (n=11) and COVID-19 patients (Mild hospitalized, n=10; Severe, n=13). Data presented as median. One-way ANOVA test: *p<0.05. (B) Heatmap of A1R, A2AR, A2BR, and A3R MFI values expression in lymphocytes and granulocytes of healthy donors (n=6) and COVID-19 patients (Mild hospitalized, n=4; Severe, n=8) based on the median of fluorescence (MFI) values. Data presented as mean. One-way ANOVA test: *p<0.05, **p<0.01. (C) MNCs from healthy donors (n=4) and COVID-19 patients (n=4) were incubated with ATP (100 μM) or ADO (100 μM) for 30 minutes. The PKA activity is shown. Data presented as median. Mann-Whitney U test: *p<0.05 (HD vs. COVID-19). Blue dots indicate healthy donors (HD) whereas orange and red dots indicate hospitalized patients with mild and severe (Sev) COVID-19, respectively.
Figure 4 Impaired ADO signaling in COVID-19 patients. (A) Gene expression of ADORA1, ADORA2A, ADORA2B, and ADORA3 in whole blood of healthy donors (n=11) and COVID-19 patients (Mild hospitalized, n=10; Severe, n=13). Data presented as median. One-way ANOVA test: *p<0.05. (B) Heatmap of A1R, A2AR, A2BR, and A3R MFI values expression in lymphocytes and granulocytes of healthy donors (n=6) and COVID-19 patients (Mild hospitalized, n=4; Severe, n=8) based on the median of fluorescence (MFI) values. Data presented as mean. One-way ANOVA test: *p<0.05, **p<0.01. (C) MNCs from healthy donors (n=4) and COVID-19 patients (n=4) were incubated with ATP (100 μM) or ADO (100 μM) for 30 minutes. The PKA activity is shown. Data presented as median. Mann-Whitney U test: *p<0.05 (HD vs. COVID-19). Blue dots indicate healthy donors (HD) whereas orange and red dots indicate hospitalized patients with mild and severe (Sev) COVID-19, respectively.CC BY · PubMed Central
Figure 5 ADO prevents cellular activation triggered by TLRs and induces anti-inflammatory responses. (A) MNCs from healthy donors (n=8) and COVID-19 patients (n=11) were incubated with ADO (100 μM) for 2 hours followed by activation with TLR7/8 agonist. Cytokine production in the supernatant after 24h is shown. (B) MNCs from healthy donors (n=8) and COVID-19 patients (n=7) were incubated with ADO (100 μM) for 24 hours and IL-10 production in the supernatant after 24h was accessed. Data are shown as the median. Wilcoxon signed-rank test: #p<0.05; ##p<0.01, ###p<0.001 (between different treatments). Mann-Whitney U test: *p<0.05 (HD vs. COVID-19). Blue dots indicate healthy donors (HD) whereas red dots indicate patients with COVID-19.
Figure 5 ADO prevents cellular activation triggered by TLRs and induces anti-inflammatory responses. (A) MNCs from healthy donors (n=8) and COVID-19 patients (n=11) were incubated with ADO (100 μM) for 2 hours followed by activation with TLR7/8 agonist. Cytokine production in the supernatant after 24h is shown. (B) MNCs from healthy donors (n=8) and COVID-19 patients (n=7) were incubated with ADO (100 μM) for 24 hours and IL-10 production in the supernatant after 24h was accessed. Data are shown as the median. Wilcoxon signed-rank test: #p<0.05; ##p<0.01, ###p<0.001 (between different treatments). Mann-Whitney U test: *p<0.05 (HD vs. COVID-19). Blue dots indicate healthy donors (HD) whereas red dots indicate patients with COVID-19.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Research works printed but not linked: 1

  1. 2020, COVID-19 therapeutic trial synopsis

Cited by

See all 24

Metadata

Authors
Pietrobon, A. J., Andrejew, R., Custódio, R. W. A., Oliveira, L. D. M., Scholl, J. N., Teixeira, F. M. E., de Brito, C. A., Glaser, T., Kazmierski, J., Goffinet, C., Turdo, A. C., Yendo, T., Aoki, V., Figueiró, F., Battastini, A. M., Ulrich, H., Benard, G., Duarte, A. J. D. S., & Sato, M. N.
Affiliations
  • Universidade de São Paulo (BR)
  • Universidade Federal do Rio Grande do Sul (BR)
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
Corresponding author
Sato, Maria Notomi
Venue
Frontiers in Immunology
Published
2022-09-30
Volume
13
Pages
1012027-1012027
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4298140749
Cited by
23
References
81
Citations by year
2026: 1 · 2025: 1 · 2024: 10 · 2023: 9 · 2022: 2
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2020/13148-0, 2018/07366-4)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.503842/2020-00)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
COVID-19 pandemic, disease severity, purinergic signaling, adenosine, extracellular ATP, ectonucleotidases, CD39, CD73, B cells, adenosine receptors, C-reactive protein, inflammation, immunopathogenesis, nucleotide metabolism
MeSH terms
COVID-19, Adenosine, Adenosine Diphosphate, Adenosine Triphosphate, Humans, Purines, Severity of Illness Index, Signal Transduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. https://app.cochat.ai/papers/10.3389/fimmu.2022.1012027
The paper
Pietrobon, A. J., Andrejew, R., Custódio, R. W. A., Oliveira, L. D. M., Scholl, J. N., Teixeira, F. M. E., de Brito, C. A., Glaser, T., Kazmierski, J., Goffinet, C., Turdo, A. C., Yendo, T., Aoki, V., Figueiró, F., Battastini, A. M., Ulrich, H., Benard, G., Duarte, A. J. D. S., & Sato, M. N. (2022). Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1012027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.